OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.
Metrics to compare | OSRH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOSRHPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.4x | −2.6x | −0.6x | |
PEG Ratio | - | −0.06 | 0.00 | |
Price/Book | 0.1x | 2.5x | 2.6x | |
Price / LTM Sales | 102.9x | 7.1x | 3.3x | |
Upside (Analyst Target) | - | 211.9% | 39.5% | |
Fair Value Upside | Unlock | 23.5% | 4.9% | Unlock |